A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity

Lassa virus (LASV) is responsible for the deaths of thousands of people in West Africa annually. Genetic diversity among LASV strains is the highest among the Arenaviridae and represents a great challenge for vaccine development. Guinea pigs vaccinated with a ML29 reassortant vaccine experienced ste...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Vaccine Ročník 25; číslo 20; s. 4093 - 4102
Hlavní autori: Carrion, Ricardo, Patterson, Jean L., Johnson, Curtis, Gonzales, Monica, Moreira, Carmen R., Ticer, Anysha, Brasky, Kathleen, Hubbard, Gene B., Moshkoff, Dmitry, Zapata, Juan, Salvato, Maria S., Lukashevich, Igor S.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Oxford Elsevier Ltd 16.05.2007
Elsevier
Elsevier Limited
Predmet:
ISSN:0264-410X, 1873-2518
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Lassa virus (LASV) is responsible for the deaths of thousands of people in West Africa annually. Genetic diversity among LASV strains is the highest among the Arenaviridae and represents a great challenge for vaccine development. Guinea pigs vaccinated with a ML29 reassortant vaccine experienced sterilizing immunity and complete protection when challenged on day 30 either with homologous virus or with the distantly related Nigerian isolate. Simultaneous vaccination–challenge or challenge on day 2 after vaccination also protected 60–100% of the animals against both strains, but without sterilizing immunity. These results indicate that simultaneous replication of ML29 and LASV attenuates the virulence of LASV infection.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Corresponding author: Igor S. Lukashevich Institute of Human Virology University of Maryland Biotechnology Institute 725 West Lombard Street, Baltimore, MD 21201 TELE: 410-706-1366; FAX 410-706-5198; email: lukashev@umbi.umd.edu
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2007.02.038